Catalogo Ricerca UNISI

Catalogo Ricerca UNISI: [80300] Home page macrotipologia

Sfoglia

1 Contributo su Rivista 48030
- 1.1 Articolo in rivista 44078
- 1.2 Recensione in rivista 1521
- 1.3 Scheda bibliografica 52
- 1.4 Nota a sentenza 636
- 1.5 Abstract in rivista 1718
- 1.6 Traduzione in rivista 25

2 Contributo in Volume 14821
- 2.1 Contributo in volume (Capitolo o Saggio) 13019
- 2.2 Prefazione/Postfazione 518
- 2.3 Breve introduzione 197
- 2.4 Voce (in dizionario o enciclopedia) 703
- 2.5 Traduzione in volume 59
- 2.6 Recensione in volume 30
- 2.7 Schede di catalogo 295

3 Libro 2851
- 3.1 Monografia o trattato scientifico 2575
- 3.2 Concordanza 4
- 3.3 Indice 9
- 3.4 Bibliografia 9
- 3.5 Edizione critica 75
- 3.6 Pubblicazione di fonti inedite 23
- 3.7 Commento scientifico 70
- 3.8 Traduzione di libro 86

4 Contributo in Atti di Convegno (Proceeding) 11102
- 4.1 Contributo in Atti di convegno 7630
- 4.2 Abstract in Atti di convegno 3123
- 4.3 Poster 349

5 Altro 893
- 5.01 Composizione 2
- 5.02 Disegno 0
- 5.03 Design 0
- 5.04 Performance 0
- 5.05 Esposizione 3
- 5.06 Mostra 19
- 5.07 Manufatto 0
- 5.08 Prototipo d'arte e relativi progetti 0
- 5.09 Cartografia 156
- 5.10 Banca dati 44
- 5.11 Software 13
- 5.12 Articolo sul sito web 110
- 5.13 Altro 546

6 Brevetti 233
- 6.1 Brevetto 233

7 Curatele 1547
- 7.1 Curatela 1547

8 Tesi di dottorato 824
- 8.1 Tesi Dottorato 824

Prodotti recenti

Update on the role of ipilimumab in melanoma and first data on new combination therapies

Purpose of reviewThis article provides an update on the therapeutic role of the monoclonal antibody ipilimumab in melanoma. Recent therapeutic combinations, as well as directions for further investigations, will also be discussed.Recent findingsBy blocking the interaction between CTLA-4 and B7 expressed on activated T lymphocytes and antigen-presenting cells, respectively, ipilimumab inhibits negative signals that physiologically downregulate T-cell activation and exerts its therapeutic activ...

Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond

Thymosin α1 (Tα1) is an immunomodulatory peptide released by the thymus gland in mammals. It was first described in 1977 as a potential agent for the treatment of immune deficiencies and cancer. Among solid tumors, a number of clinical trials have investigated the activity of Tα1 in melanoma. In particular, a large randomized phase II trial that evaluated the safety and efficacy of combining Tα1 with dacarbazine and interferon alpha in metastatic melanoma patients provided the rationale for f...

The cost of unresectable stage III or stage IV melanoma in Italy

Background: In recent decades, melanoma incidence has been increasing in European countries; in 2006, there were approximately 60,000 cases leading to 13,000 deaths. Within Europe there is some geographical variation in the incidence of melanoma, with the highest rates reported in Scandinavia (15 cases per 100,000 inhabitants per year) and the lowest in the Mediterranean countries (5 to 7 cases per 100,000 inhabitants per year).Methods: The present article is based on the information collecte...

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

BACKGROUND: Ipilimumab improves survival of patients with metastatic melanoma, many of whom develop brain metastases. Chemotherapy-induced release of tumour antigens might amplify ipilimumab's antitumour activity. We aimed to investigate the efficacy and safety of ipilimumab plus fotemustine in patients with metastatic melanoma with or without asymptomatic brain metastases. METHODS: In our open-label, single-arm phase 2 trial, we enrolled patients 18 years or older with measurable, locally ad...

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

Background: Monoclonal antibodies to cytotoxic T-lymphocyte antigen 4 (CTLA4) have therapeutic activity in different tumour types. We aimed to investigate the efficacy, safety, and immunological activity of the anti-CTLA4 monoclonal antibody, tremelimumab, in advanced malignant mesothelioma. Methods: In our open-label, single-arm, phase 2 study, we enrolled patients aged 18 years or older with measurable, unresectable malignant mesothelioma and progressive disease after a first-line platinum-...

Scopri

Accesso al fulltext

no fulltext45180
reserved27754
open6356
partially open687
restricted136
internalNetwork111
embargoed63
mixed13